These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30136888)

  • 41. Penetration and effectiveness of prophylactic fluoroquinolones in experimental methicillin-sensitive or methicillin-resistant Staphylococcus aureus anterior chamber infections.
    Balzli CL; Caballero AR; Tang A; Weeks AC; O'Callaghan RJ
    J Cataract Refract Surg; 2010 Dec; 36(12):2160-7. PubMed ID: 21111321
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro and in vivo effectiveness evaluation of balofloxacin in experimental Staphylococcus aureus keratitis.
    Jiang H; Han S; Guo C; Liu T; Wu X
    J Ocul Pharmacol Ther; 2014 Aug; 30(6):482-8. PubMed ID: 24828089
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
    DeLeon J; Silverstein BE; Allaire C; Gearinger LS; Bateman KM; Morris TW; Comstock TL
    Clin Drug Investig; 2012 May; 32(5):303-17. PubMed ID: 22420526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simultaneous quantification of gatifloxacin, moxifloxacin, and besifloxacin concentrations in cornea and aqueous humor by LC-QTOF/MS after topical ocular dosing.
    Domingos LC; Moreira MV; Keller KM; Viana FA; Melo MM; Soto-Blanco B
    J Pharmacol Toxicol Methods; 2017; 83():87-93. PubMed ID: 27670369
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Levofloxacin (Tavanic) in the treatment of corneal ulcers].
    Maĭchuk IuF
    Antibiot Khimioter; 2003; 48(6):16-9. PubMed ID: 14558414
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chitosan Nanoparticles as a Mucoadhesive Drug Delivery System for Ocular Administration.
    Silva MM; Calado R; Marto J; Bettencourt A; Almeida AJ; Gonçalves LMD
    Mar Drugs; 2017 Dec; 15(12):. PubMed ID: 29194378
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design and Development of Thermoreversible Ophthalmic In Situ Hydrogel of Moxifloxacin HCl.
    Shastri DH; Prajapati ST; Patel LD
    Curr Drug Deliv; 2010 Jul; 7(3):238-43. PubMed ID: 20497100
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
    DeCory HH; Sanfilippo CM; Proskin HM; Blondeau JM
    PLoS One; 2020; 15(8):e0237603. PubMed ID: 32841261
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Moxifloxacin loaded gelatin nanoparticles for ocular delivery: Formulation and in-vitro, in-vivo evaluation.
    Mahor A; Prajapati SK; Verma A; Gupta R; Iyer AK; Kesharwani P
    J Colloid Interface Sci; 2016 Dec; 483():132-138. PubMed ID: 27552421
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of besifloxacin HCl loaded nanofibrous ocular inserts for the treatment of bacterial keratitis: In vitro, ex vivo and in vivo evaluation.
    Polat HK; Bozdağ Pehlivan S; Özkul C; Çalamak S; Öztürk N; Aytekin E; Fırat A; Ulubayram K; Kocabeyoğlu S; İrkeç M; Çalış S
    Int J Pharm; 2020 Jul; 585():119552. PubMed ID: 32569814
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comprehensive evaluation of formulation factors for ocular penetration of fluoroquinolones in rabbits using cassette dosing technique.
    Sharma C; Biswas NR; Ojha S; Velpandian T
    Drug Des Devel Ther; 2016; 10():811-23. PubMed ID: 26955263
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis.
    Tepedino ME; Heller WH; Usner DW; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL
    Curr Med Res Opin; 2009 May; 25(5):1159-69. PubMed ID: 19323612
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.
    Haas W; Gearinger LS; Hesje CK; Sanfilippo CM; Morris TW
    Adv Ther; 2012 May; 29(5):442-55. PubMed ID: 22644963
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prophylactic effect of topical fluoroquinolones in a rabbit model of Staphylococcus aureus endophthalmitis.
    Wu X; Chen H; Jiang H; Xu Y; Liu T; Xu L
    J Ocul Pharmacol Ther; 2012 Apr; 28(2):186-93. PubMed ID: 22077488
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration.
    Healy DP; Holland EJ; Nordlund ML; Dunn S; Chow C; Lindstrom RL; Hardten D; Davis E
    Cornea; 2004 Apr; 23(3):255-63. PubMed ID: 15084858
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis.
    Malhotra R; Ackerman S; Gearinger LS; Morris TW; Allaire C
    Drugs R D; 2013 Dec; 13(4):243-52. PubMed ID: 24142473
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application.
    Donnenfeld ED; Comstock TL; Proksch JW
    J Cataract Refract Surg; 2011 Jun; 37(6):1082-9. PubMed ID: 21596251
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glycol chitosan/oxidized hyaluronic acid hydrogel film for topical ocular delivery of dexamethasone and levofloxacin.
    Bao Z; Yu A; Shi H; Hu Y; Jin B; Lin D; Dai M; Lei L; Li X; Wang Y
    Int J Biol Macromol; 2021 Jan; 167():659-666. PubMed ID: 33278439
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty.
    Fukuda M; Yamada M; Kinoshita S; Inatomi T; Ohashi Y; Uno T; Shimazaki J; Satake Y; Maeda N; Hori Y; Nishida K; Kubota A; Nakazawa T; Shimomura Y
    Adv Ther; 2012 Apr; 29(4):339-49. PubMed ID: 22529026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer.
    Bíró T; Horvát G; Budai-Szűcs M; Csányi E; Urbán E; Facskó A; Szabó-Révész P; Csóka I; Aigner Z
    Drug Des Devel Ther; 2018; 12():2529-2537. PubMed ID: 30147300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.